TRCT
ATHE

Tower Research Capital (TRC)’s Alterity Therapeutics ATHE Stock Holding History

Tower Research Capital (TRC)’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed -$31 – 5120
2025
Q4 		$31 Buy
+10
New +$38 ﹤0.01% 5088
2020
Q3 		– Sell
-1
Closed – – 4810
2020
Q2 		$0 Buy
+1
New +$6 ﹤0.01% 4724
2017
Q1 		– Sell
-51
Closed -$1K – 3034
2016
Q4 		$1K Buy
+51
New +$1.36K ﹤0.01% 3563
2016
Q1 		– Sell
-6
Closed – – 4088
2015
Q4 		$0 Sell
6
-131
-96% -$6.66K ﹤0.01% 4451
2015
Q3 		$7K Buy
137
+20
+17% +$1.27K ﹤0.01% 2544
2015
Q2 		$8K Sell
117
-80
-41% -$6.01K ﹤0.01% 2868
2015
Q1 		$13K Buy
197
+185
+1,542% +$14.8K ﹤0.01% 2574
2014
Q4 		$1K Sell
12
-137
-92% -$14.8K ﹤0.01% 3586
2014
Q3 		$19K Buy
149
+145
+3,625% +$19.4K ﹤0.01% 2327
2014
Q2 		$1K Buy
+4
New +$456 ﹤0.01% 3615
2014
Q1 		– Sell
-47
Closed -$20K – 4411
2013
Q4 		$20K Sell
47
-143
-75% -$42.8K ﹤0.01% 2321
2013
Q3 		$47K Buy
190
+109
+135% +$25K 0.01% 1956
2013
Q2 		$11K Buy
+81
New +$11K ﹤0.01% 2251

Other funds holding ATHE

TLCM
Twin Lakes Capital Management Redwood Shores, California $262M AUM 60.26% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Tower Research Capital (TRC)'s ATHE Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Alterity Therapeutics (ATHE) in Q1 2026, closing a stake of 10 shares — an estimated $31 sold.

Tower Research Capital (TRC) first reported a position in ATHE in Q2 2013 and held it in 13 quarters. The position peaked at $47K in Q3 2013. 15 funds tracked by Wall St. Rank hold ATHE as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Alterity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 10 Alterity Therapeutics shares in Q1 2026, an estimated $31.
  • Tower Research Capital (TRC) first reported a position in Alterity Therapeutics in Q2 2013 and held it in 13 quarters.
  • Tower Research Capital (TRC)'s Alterity Therapeutics position peaked at $47K in Q3 2013.
  • 15 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.